Join to view full profile
2646 E Banner Gateway DriveGilbert, AZ 85234
Phone+1 480-256-6444
Fax+1 480-256-4734
Dr. Mashni is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Corewell Health William Beaumont University HospitalResidency, Urology, 2008 - 2012- Corewell Health William Beaumont University HospitalResidency, Surgery, 2006 - 2008
Loma Linda University School of MedicineClass of 2006
Certifications & Licensure
AZ State Medical License 2014 - 2028
NY State Medical License 2012 - 2027
MI State Medical License 2006 - 2012
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2016
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2016
Publications & Presentations
PubMed
- 4 citationsBiodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer pa...Aaron A Laviana, Elizabeth G Schiftan, Joseph W Mashni, Michael C Large, Hristos Z Kaimakliotis
Urologic Oncology. 2023-06-01 - 18 citationsAntiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of...Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, Tanner Miest, Stephen A Boorjian
European Urology. 2022-03-01 - 335 citationsIntravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella
The Lancet. Oncology. 2021-01-01
Press Mentions
Banner MD Anderson First Hospital in Arizona to Offer Novel Prostate Cancer TreatmentJune 26th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: